Anguita Sánchez Manuel, Ojeda Pineda Soledad
Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain.
Rev Esp Cardiol. 2006 Jul;6 Suppl F:53-8. doi: 10.1157/13091625.
Diastolic heart failure (i.e., heart failure with preserved systolic function) accounts for 30%-50% of all cases of heart failure. Prognosis is almost as poor as with systolic heart failure. Currently, the only requirements for diagnosis are that strict clinical criteria for heart failure are satisfied and that the left ventricular ejection fraction is preserved (i.e., greater than 40%-50%), although in the future measurement of brain natriuretic peptides could be useful. Because of a lack of evidence from large clinical trials, with the exception of the CHARM study which showed that candesartan slightly reduced the hospital readmission rate, therapy is based on the identification and treatment of the causal condition (e.g., hypertension or coronary heart disease), heart rate control, and relief of congestion. Thus, combination treatment with low-dose diuretics, bradycardiac antihypertensives (e.g., beta-blockers or calcium antagonists), and angiotensin antagonists currently seems to be the best therapeutic approach.
舒张性心力衰竭(即收缩功能保留的心力衰竭)占所有心力衰竭病例的30% - 50%。其预后几乎与收缩性心力衰竭一样差。目前,诊断的唯一要求是满足心力衰竭的严格临床标准且左心室射血分数保留(即大于40% - 50%),不过未来脑钠肽的测量可能会有帮助。由于缺乏大型临床试验的证据,除了CHARM研究表明坎地沙坦可略微降低住院再入院率外,治疗基于对病因(如高血压或冠心病)的识别与治疗、心率控制以及缓解充血。因此,目前低剂量利尿剂、减慢心率的抗高血压药物(如β受体阻滞剂或钙拮抗剂)和血管紧张素拮抗剂的联合治疗似乎是最佳治疗方法。